Announcement 01.12.23 Share on Twitter Share on Facebook Share on LinkedIn PICI Network Researchers to Present on Cellular Therapies at Keystone Symposia Ten investigators from the Parker Institute for Cancer Immunotherapy (PICI) Network will discuss cellular immunotherapies for hematological malignancies and solid tumors, at the Keystone Symposia on Molecular and Cellular Biology, Jan. 29-Feb. 2 in Banff, Alberta. The conference, titled “Emerging Cellular Therapies at the Forefront of Cancer Immunotherapy,” incorporates broad expertise, aiming to propose an integrated path toward successful implementation of novel cellular therapeutics, particularly for solid tumors. PICI Network member Lisa Butterfield, PhD, of the University of California, San Francisco is one of four scientific organizers of the conference. Crystal Mackall, MD, (Twitter: @MackallLab) director of the Parker Institute for Cancer Immunotherapy at Stanford Medicine, will deliver the conference welcome and keynote address, “CAR T Cells for Solid Tumors,” on Jan. 30. Below are other sessions featuring PICI Network investigators. Please note that all events listed are subject to change. For the most current information, visit the conference program. Follow the meeting live on Twitter using the hashtag #KSCellTherapy23. Jan. 30 Session: T-Cell Factors Affecting the Potency of Cancer Immunotherapies Presenter: Zachary Steinhart, PhD, (Twitter: @CrisprEh) Gladstone-UCSF Institute of Genomic Immunology Presentation: Genome-wide CRISPR Activation and Interference Screens Discover Key Drivers of Primary Human T Cell Function Jan. 31 Session: Conditional Reprogramming of CAR T-Cells Presenter: Daniel Powell Jr., PhD, University of Pennsylvania Presentation: Inducible Programming of CAR T cell Function and Intrinsic Properties for Cancer Immunotherapy Presenter: Robbie Majzner, MD, (Twitter: @Majzner_Lab), Stanford Medicine Presentation: Co-opting T Cell Signaling Networks for Enhanced CAR T Cell Specificity and Efficacy Session: Improving Expansion and Persistence Adoptive T-Cell Therapies Presenter: Justin Eyquem, PhD, (Twitter: @J_Eyquem), University of California, San Francisco Presentation: Modification of CAR Signaling Domain Presenter: Yvonne Chen, PhD, University of California, Los Angeles Presentation: Engineering Next-Generation CAR-T Cell Therapy for Cancer Feb. 1 Session: Cell Trafficking and Modulating the Tumor Microenvironment Presenter: Christopher Klebanoff, MD, Memorial Sloan Kettering Cancer Center Presentation: Targeting Solid Malignancies With Patient-Derived ‘Public’ Neoantigen TCRs Session: Engineering Improved T-Cells Presenter: Kole Roybal, PhD, (Twitter: @KoleRoybal) University of California, San Francisco Presentation: Engineering T-Cells to Express Receptors Targeting Multiple Antigens Feb. 2 Session: Novel Targets and the Role of Endogenous Antigen Presentation Presenter: Catherine Wu, MD, Dana-Farber Cancer Institute Presentation: T-Cell Therapy using Neoantigen Reactive TCRs Presenter: Lisa Butterfield, PhD, of the University of California, San Francisco Presentation: Critical Aspects of DC Metabolism Related Announcement PICI 2024: Collaborative Breakthroughs in Cancer Immunotherapy Announcement, Press Release Parker Institute Awards $525,000 to Advance Diverse Talent in Cancer Research Announcement PICI Network Investigators Propel Immunotherapy Progress at SITC 2024
Announcement, Press Release Parker Institute Awards $525,000 to Advance Diverse Talent in Cancer Research